Document Basket

Saved pages

Saved documents

Please note: This information is saved in a cookie. In case your browser deletes cookies after a session, the information will be lost.

DKSH to further drive sales growth for Cheplapharm in seven Asian markets 2018-01-09

Back
DKSH to further drive sales growth for Cheplapharm in seven Asian markets

DKSH, the leading Market Expansion Services provider with a focus on Asia, and Cheplapharm Arzneimittel GmbH, a German family-owned pharmaceutical company that offers branded products globally, have signed a deal to drive sales growth for its business in seven Asian markets.

Media release

DKSH to further drive sales growth for Cheplapharm in seven Asian markets

DKSH, the leading Market Expansion Services provider with a focus on Asia, and Cheplapharm Arzneimittel GmbH, a German family-owned pharmaceutical company that offers branded products globally, have signed a deal to drive sales growth for its business in seven Asian markets.

Bangkok, Thailand, January 9, 2018 – DKSH Business Unit Healthcare, a leading Market Expansion Services provider for healthcare companies seeking to grow their business in Asia, has started a collaboration with Cheplapharm to renew sales growth of its branded products across Asia.

 

DKSH will provide marketing, sales, distribution and logistics services for the products across pharmacies, hospitals and clinics in Thailand, Malaysia, Singapore, Myanmar, Cambodia, Hong Kong and Macau. In this way DKSH will support Cheplapharm in renewing growth for their established products.

 

“We selected DKSH for the company’s extensive experience managing sales and distributing products across Asia. Their extensive network across healthcare decision makers will help us make our products available for people who need it. We are impressed by and value DKSH’s experience and expertise in the region and are looking forward to mutually develop and foster a trustful and professional partnership with our new business partners,” said Edeltraud Lafer, Chief Operating Officer of Cheplapharm.

 

“Our in-depth knowledge of the local markets and well-established distribution network across Asia allows us to provide regional solutions and duplicate success across markets. With the largest dedicated salesforce in Asia and an unwavering commitment to quality and compliance, we are keen to increase sales for our new partner Cheplapharm,” said Bijay Singh, Head, Business Unit Healthcare, DKSH.

About Cheplapharm Arzneimittel GmbH

Cheplapharm is a family owned pharmaceutical company with its headquarters situated in Germany and offering branded products on a global level. The company focuses on an internationally oriented Buy and Build Strategy. In close collaboration with its business partners, Cheplapharm generates sustainable annual growth rates. Cheplapharm specializes in selected active substances and indications and commits itself to provide branded products of high quality and to guarantee continuous availability to its costumers. Please refer to www.cheplapharm.com for additional information.

 

About DKSH

DKSH is the leading Market Expansion Services provider with a focus on Asia. As the term "Market Expansion Services" suggests, DKSH helps other companies and brands to grow their business in new or existing markets. Publicly listed on the SIX Swiss Exchange since 2012, DKSH is a global company headquartered in Zurich. With 780 business locations in 36 countries – 750 of them in Asia – and 30,320 specialized staff, DKSH generated net sales of CHF 10.5 billion in 2016. DKSH was founded in 1865. With strong Swiss heritage, the company has a long tradition of doing business in and with Asia and is deeply rooted in communities and businesses across Asia Pacific.

 

DKSH Business Unit Healthcare is the leading Market Expansion Services provider for healthcare companies seeking to grow their business in Asia. Custom-made offerings comprise registration, regulatory services, market entry studies, importation, customs clearance, marketing and sales, capillary physical distribution, invoicing and cash collection. Products available through DKSH Healthcare include pharmaceuticals, consumer health and over-the-counter (OTC) products as well as medical devices. With 120 business locations in 13 countries and around 9,740 specialized staff, Business Unit Healthcare serves over 150,000 customers and generated net sales of CHF 5.5 billion in 2016.

 

For further information please contact:

 

DKSH Holding Ltd.

 

Till Leisner

Head, Group Investor & Media Relations

Phone +41 44 386 7315

till.leisner@dksh.com

Dominique Nadelhofer

Manager, Group Media Relations

Phone +41 44 386 7228

dominique.nadelhofer@dksh.com

Downloads

Select a country